Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Directly targeting PRDM16 in thermogenic adipose tissue to treat obesity and its related metabolic diseases

Mao L., Lu J., Hou Y., Nie T.

Narrative Review on Systemic / IV, published in Front Endocrinol (Lausanne) (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Endocrinol (Lausanne) (2024)
Reported sample size
—
Source database
Europe PMC
PMID
39351529
PMCID
PMC11439700
DOI
10.3389/fendo.2024.1458848
Citations
14

Abstract (original English)

Obesity is increasing globally and is closely associated with a range of metabolic disorders, including metabolic associated fatty liver disease, diabetes, and cardiovascular diseases. An effective strategy to combat obesity involves stimulating brown and beige adipocyte thermogenesis, which significantly enhances energy expenditure. Recent research has underscored the vital role of PRDM16 in the development and functionality of thermogenic adipocytes. Consequently, PRDM16 has been identified as a potential therapeutic target for obesity and its related metabolic disorders. This review comprehensively examines various studies that focus on combating obesity by directly targeting PRDM16 in adipose tissue.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsHumansMetabolic DiseasesObesityDNA-Binding ProteinsTranscription FactorsEnergy MetabolismThermogenesisAdipose Tissue, Brown

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research